Investigational Site Number :1560035

Beijing 100730

2 studies enrolling now · 3 studies all time

What they study most

Breast Cancer, Chronic Obstructive Pulmonary Disease, Type 1 Diabetes Mellitus

Studies at this site

• A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes — Recruiting now
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype — Recruiting now
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early